Correction: Corrigendum: Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity
Scientific Reports2017Vol. 7(1)
Citations Over TimeTop 10% of 2017 papers
Yukti Choudhury, Yi‐Chin Toh, Jiangwa Xing, Yinghua Qu, Jonathan Poh, Huan Li, Hui Shan Tan, Ravindran Kanesvaran, Hanry Yu, Min‐Han Tan
Abstract
Scientific Reports 7: Article number: 41238; published online: 25 January 2017; updated: 25 April 2017 The original version of this Article contained an error in the spelling of the author Huan Li, which was incorrectly given as Li Huan. The Author Contributions Statement, Study concept and design: Y.
Related Papers
- → Oral Side Effects in Patients with Metastatic Renal Cell Carcinoma Receiving the Antiangiogenic Agent Pazopanib—Report of Three Cases(2022)9 cited
- → Tumors Sharply Increased after Ceasing Pazopanib Therapy for a Patient with Advanced Uterine Leiomyosarcoma: Experience of Tumor Flare(2017)3 cited
- → Pazopanib-Induced Alopecia, an Underestimated Toxicity?(2015)5 cited
- → Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience(2018)3 cited
- → Heart Failure Secondary to Pazopanib for Treatment of Metastatic Renal Cell Carcinoma(2016)